Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and kinase inhibitor in nonclinical tumor models at AACR
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that data from the company's leading program fostroxacitabine bralpamide (fostrox) and its potential effect on hepatocellular carcinoma (HCC), will be presented at the American Association for Cancer Research (AACR) Annual Meeting, on April 14-19, in Orlando, USA. The abstract, titled “A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor